Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Blanchard Valley Medical Associates
mi
from
Findlay, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Blanchard Valley Medical Associates
mi
from
Findlay, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Middletown Regional Hospital
mi
from
Middletown, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Middletown Regional Hospital
mi
from
Middletown, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Air Force Base, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
United States Air Force Medical Center - Wright-Patterson
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Tod Children's Hospital - Forum Health
mi
from
Youngstown, OH
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Tod Children's Hospital - Forum Health
mi
from
Youngstown, OH
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Emanuel Hospital and Health Center & Children's Hospital
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Emanuel Hospital and Health Center & Children's Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University Cancer Institute
mi
from
Portland, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Salem Hospital Regional Cancer Care Services
mi
from
Salem, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Salem Hospital Regional Cancer Care Services
mi
from
Salem, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Legacy Meridian Park Hospital
mi
from
Tualatin, OR
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Legacy Meridian Park Hospital
mi
from
Tualatin, OR
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Bon Secours St. Francis Health System
mi
from
Greenville, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Greenville
mi
from
Greenville, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
CCOP - Scott and White Hospital
mi
from
Temple, TX
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
St. Joseph Cancer Center
mi
from
Bellingham, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
St. Joseph Cancer Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Olympic Hematology and Oncology
mi
from
Bremerton, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Olympic Hematology and Oncology
mi
from
Bremerton, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Minor and James Medical, PLLC
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Minor and James Medical, PLLC
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Group Health Capitol Hill Campus
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Group Health Capitol Hill Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Polyclinic First Hill
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Polyclinic First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
North Star Lodge
mi
from
Yakima, WA
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
HealthAlliance Hospitals
mi
from
Fitchburg, MA
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
HealthAlliance Hospitals
mi
from
Fitchburg, MA
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Cancer Center
mi
from
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
Quality of Life in Younger Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
mi
from
Monterey, CA
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
Quality of Life in Younger Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
mi
from
Monterey, CA
Click here to add this to my saved trials